Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220034/S007

LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus

DiaSorin, Inc. · Decision date Oct 10, 2025

FDA DECISIONP220034/S007

What did the FDA approve?

FDA records P220034/S007 as a supplement to PMA P220034, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Oct 10, 2025.

FDA approval order statement

Approval for the use of an alternative polypropylene resin for production of the plastic vials hosting the LIAISON assays reagents
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Microbiology
Decision date
Oct 10, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P220034/S007
Regulatory pathway
PMA supplement
Product code
MYL
Decision code
APPR
Decision date
Oct 10, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGG.

Product code
MYL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P220034/S007 received

    Application receipt date recorded by FDA.

  2. P220034/S007 · FDA decision

    Real-Time Process

  3. P220034/S008 · Related supplement

    LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus

  4. P220034/S011 · Related supplement

    LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus

  5. P220034/S010 · Related supplement

    LIAISON Biotrin Parvovirus B19 IgG Plus; LIAISON Biotrin Control Parvovirus B19 IgG Plus

Timeline entries are records held by MedtechLedger for P220034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220034

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

DiaSorin, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1951 Northwestern Ave., Stillwater, MN, 55082

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records